Literature DB >> 19152679

A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis.

Rolf I Skotheim1, Gard O S Thomassen, Marthe Eken, Guro E Lind, Francesca Micci, Franclim R Ribeiro, Nuno Cerveira, Manuel R Teixeira, Sverre Heim, Torbjørn Rognes, Ragnhild A Lothe.   

Abstract

BACKGROUND: The ability to detect neoplasia-specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal treatment is chosen. However, the available methodologies to detect such fusions all have their distinct short-comings.
RESULTS: We describe a novel oligonucleotide microarray strategy whereby one can screen for all known oncogenic fusion transcripts in a single experiment. To accomplish this, we combine measurements of chimeric transcript junctions with exon-wise measurements of individual fusion partners. To demonstrate the usefulness of the approach, we designed a DNA microarray containing 68,861 oligonucleotide probes that includes oligos covering all combinations of chimeric exon-exon junctions from 275 pairs of fusion genes, as well as sets of oligos internal to all the exons of the fusion partners. Using this array, proof of principle was demonstrated by detection of known fusion genes (such as TCF3:PBX1, ETV6:RUNX1, and TMPRSS2:ERG) from all six positive controls consisting of leukemia cell lines and prostate cancer biopsies.
CONCLUSION: This new method bears promise of an important complement to currently used diagnostic and research tools for the detection of fusion genes in neoplastic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19152679      PMCID: PMC2633275          DOI: 10.1186/1476-4598-8-5

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  21 in total

1.  Minimum information about a microarray experiment (MIAME)-toward standards for microarray data.

Authors:  A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

2.  Screening and quantification of multiple chromosome translocations in human leukemia.

Authors:  Run Zhang Shi; Joseph M Morrissey; Janet D Rowley
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

3.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Authors:  Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

4.  Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs).

Authors:  Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

5.  Identification of chromosomal translocations in leukemias by hybridization with oligonucleotide microarrays.

Authors:  Tatyana Nasedkina; Peter Domer; Vladislav Zharinov; James Hoberg; Yuri Lysov; Andrei Mirzabekov
Journal:  Haematologica       Date:  2002-04       Impact factor: 9.941

6.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Authors:  Beth E Helgeson; Scott A Tomlins; Nameeta Shah; Bharathi Laxman; Qi Cao; John R Prensner; Xuhong Cao; Nirmish Singla; James E Montie; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

Authors:  Peter J Campbell; Philip J Stephens; Erin D Pleasance; Sarah O'Meara; Heng Li; Thomas Santarius; Lucy A Stebbings; Catherine Leroy; Sarah Edkins; Claire Hardy; Jon W Teague; Andrew Menzies; Ian Goodhead; Daniel J Turner; Christopher M Clee; Michael A Quail; Antony Cox; Clive Brown; Richard Durbin; Matthew E Hurles; Paul A W Edwards; Graham R Bignell; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2008-04-27       Impact factor: 38.330

Review 8.  Recurrent fusion oncogenes in carcinomas.

Authors:  Manuel R Teixeira
Journal:  Crit Rev Oncog       Date:  2006-12

9.  TICdb: a collection of gene-mapped translocation breakpoints in cancer.

Authors:  Francisco J Novo; Iñigo Ortiz de Mendíbil; José L Vizmanos
Journal:  BMC Genomics       Date:  2007-01-26       Impact factor: 3.969

10.  Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.

Authors:  Sameer Jhavar; Alison Reid; Jeremy Clark; Zsofia Kote-Jarai; Timothy Christmas; Alan Thompson; Christopher Woodhouse; Christopher Ogden; Cyril Fisher; Cathy Corbishley; Johann De-Bono; Rosalind Eeles; Daniel Brewer; Colin Cooper
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

View more
  13 in total

Review 1.  New fusion sarcomas: histopathology and clinical significance of selected entities.

Authors:  Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota
Journal:  Hum Pathol       Date:  2019-01-08       Impact factor: 3.466

2.  Rapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays.

Authors:  Harvey A Greisman; Noah G Hoffman; Hye Son Yi
Journal:  J Mol Diagn       Date:  2011-09-09       Impact factor: 5.568

3.  Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA.

Authors:  Roberto Plebani; Gavin R Oliver; Marco Trerotola; Emanuela Guerra; Pamela Cantanelli; Luana Apicella; Andrew Emerson; Alessandro Albiero; Paul D Harkin; Richard D Kennedy; Saverio Alberti
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 4.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

5.  Antibody detection of translocations in Ewing sarcoma.

Authors:  Wen Luo; Brett Milash; Brian Dalley; Richard Smith; Holly Zhou; Natalie Dutrow; Bradley R Cairns; Stephen L Lessnick
Journal:  EMBO Mol Med       Date:  2012-03-15       Impact factor: 12.137

6.  Molecular investigation of Ewing sarcoma: about detecting translocations.

Authors:  Olga Blau
Journal:  EMBO Mol Med       Date:  2012-03-29       Impact factor: 12.137

7.  Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples.

Authors:  Serban Nacu; Wenlin Yuan; Zhengyan Kan; Deepali Bhatt; Celina Sanchez Rivers; Jeremy Stinson; Brock A Peters; Zora Modrusan; Kenneth Jung; Somasekar Seshagiri; Thomas D Wu
Journal:  BMC Med Genomics       Date:  2011-01-24       Impact factor: 3.063

8.  Detecting cancer outlier genes with potential rearrangement using gene expression data and biological networks.

Authors:  Mohammed Alshalalfa; Tarek A Bismar; Reda Alhajj
Journal:  Adv Bioinformatics       Date:  2012-06-28

9.  Custom design and analysis of high-density oligonucleotide bacterial tiling microarrays.

Authors:  Gard O S Thomassen; Alexander D Rowe; Karin Lagesen; Jessica M Lindvall; Torbjørn Rognes
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

10.  Assessment of fusion gene status in sarcomas using a custom made fusion gene microarray.

Authors:  Marthe Løvf; Gard O S Thomassen; Fredrik Mertens; Nuno Cerveira; Manuel R Teixeira; Ragnhild A Lothe; Rolf I Skotheim
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.